Table 1. Baseline patient characteristics, stratified by ever versus never receiving biologics or surgery.
The HS cohort was representative of patients with HS in the United States with a predominantly female and African American population. The majority of patients had active disease at baseline as evidenced by Hurley stage and mHSS score at baseline.
| Patient Variable | All HS Patients (n=68) |
OPIOIDS | SURGERY | BIOLOGICS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Ever (n=39) |
Never (n=29) |
P | Ever (n=31) |
Never (n=37) |
P | Ever (n=31) |
Never (n=37) |
P | |||
|
| |||||||||||
| Mean age at baseline, years (±SD) | 40.4 (14) | 39.5 (13) | 41.6 (16) | 0.60 | 38 (13) | 41 (15) | 0.38 | 37 (12) | 42 (16) | 0.21 | |
|
| |||||||||||
| Gender, female | 45 (66%) | 23 (59%) | 22 (76%) | 0.15 | 17 (55%) | 28 (76%) | 0.07 | 18 (58%) | 27 (73%) | 0.20 | |
|
| |||||||||||
| Race | |||||||||||
| African American | 49 (72%) | 29 (74%) | 20 (69%) | 0.55 | 21 (68%) | 28 (76%) | 0.48 | 20 (65%) | 29 (78%) | 0.31 | |
| Caucasian | 18 (26%) | 9 (23%) | 9 (31.0%) | 9 (29%) | 9 (24%) | 10 (32%) | 8 (22%) | ||||
| Asian | 1 (1%) | 1 (3%) | 0 | 1 (3%) | 0 | 1 (3%) | 0 | ||||
|
| |||||||||||
| Body Mass Index (BMI, Kg/m2) | 34 (8) | 34 (9) | 35 (6) | 0.75 | 35 (9) | 33 (6) | 0.35 | 35 (8) | 34 (8) | 0.83 | |
|
| |||||||||||
| Current smoker | 15 (22%)) | 13 (33%) | 2 (7%) | 0.009 | 10 (32%) | 5 (14%) | 0.06 | 7 (23%) | 8 (22%) | 0.92 | |
|
| |||||||||||
| Diabetes Mellitus | 10 (15%) | 7 (18%) | 3 (10%) | 0.50 | 4 (13%) | 6 (16%) | 0.75 | 6 (19%) | 4 (11%) | 0.49 | |
|
| |||||||||||
| Hypertension | 17 (25%) | 13 (33%) | 4 (14%) | 0.07 | 11 (35%) | 6 (16%) | 0.07 | 7 (23%) | 10 (27%) | 0.67 | |
|
| |||||||||||
| Mean disease duration, years (±SD) | 10 (12) | 10 (11) | 11 (14) | 0.63A | 9 (9) | 12 (14) | 0.54A | 9 (7) | 12 (15) | 0.53A | |
|
| |||||||||||
| Baseline AN count | 3.4 (1.9) | 3.6 (1.6) | 3.1 (2.3) | 0.42 | 3.4 (1.7) | 3.4 (2.1) | 0.94 | 3.9 (1.8) | 2.9 (1.9) | 0.026 | |
|
| |||||||||||
| Baseline Hurley Stage | |||||||||||
| 0 | 2 (3%) | 0 | 2 (7%) | 0.004 | 0 | 2 (5%) | 0.22 | 1 (3%) | 1 (3%) | 0.24 | |
| I | 6 (9%) | 4 (10%) | 2 (7%) | 2 (6%) | 4 (11%) | 2 (6%) | 4 (11%) | ||||
| II | 13 (19%) | 2 (5%) | 11 (38%) | 4 (13%) | 9 (24%) | 3 (10%) | 10 (27%) | ||||
| III | 43 (63%) | 30 (77%) | 13 (45%) | 24 (77%) | 19 (51%) | 24 (77%) | 19 (51%) | ||||
| Post-surgical | 4 (6%) | 3 (8%) | 1 (3%) | 1 (3%) | 3 (8%) | 1 (3%) | 3 (8%) | ||||
|
| |||||||||||
| Mean baseline HSS (±SD) | 61 (46) | 71 (43) | 49 (48) | 0.02A | 66 (42) | 57 (49) | 0.42 | 75 (47) | 49 (42) | 0.014 | |
|
| |||||||||||
| Pain VAS (±SD) | 3.7 (3.5) | 4.4 (3.6) | 2.7 (3.2) | 0.07A | 4.4 (3.2) | 3.1 (3.7) | 0.07A | 4.1 (3.5) | 3.3 (3.5) | 0.46A | |
|
| |||||||||||
| Visits | 12 (9) | 15 (10) | 7 (5) | <0.0001 | 18 (10) | 6 (5) | <0.0001 | 17 (10) | 7 (6) | <0.0001 | |
(A Kruskal-Wallis test used due to skewed distributions).